Search results for "drug eluting stent"

showing 3 items of 3 documents

Sicilian DES Registry: prospective in-hospital and 9-month clinical and angiographic follow-up in selected high restenosis risk patients.

2008

OBJECTIVE: This is a multicentre, open label, prospective non-randomized registry, with 9-month angiographic follow-up, conducted to evaluate the safety and effectiveness of drug-eluting stents (DES) when used in high restenosis risk patients from the real world. METHODS: From June 2004 to February 2005, a total of 1622 consecutive patients were enrolled to the Sicilian DES Registry, according to specific inclusion criteria. Both paclitaxel-eluting and sirolimus-eluting stents were used. The analysis was performed on 1472 patients because 150 patients were excluded from the study. The primary endpoint was to evaluate the rate of major adverse cardiac events (MACE) within 9 months after DES …

Malemedicine.medical_specialtyPaclitaxelCoronary angioplastyRegistry.Target vessel revascularizationCoronary DiseaseCoronary AngiographyCoronary artery diseaseCoronary RestenosisRestenosisClinical endpointMedicineHumansCumulative incidencecardiovascular diseasesMyocardial infarctionDrug eluting stentRegistriesAngioplasty Balloon CoronarySicilyAgedSirolimusEjection fractionbusiness.industryIncidence (epidemiology)Drug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseSurgeryFemaleCardiology and Cardiovascular MedicinebusinessMaceDiabetic AngiopathiesImmunosuppressive AgentsJournal of cardiovascular medicine (Hagerstown, Md.)
researchProduct

Bioresorbable vascular scaffold versus everolimus-eluting stents or drug eluting balloon for the treatment of coronary in-stent restenosis: 1-Year fo…

2017

Objectives to compare the 1-year outcome between bioresorbable vascular scaffold (BVS), everolimus-eluting stent (EES), and drug-eluting balloon (DEB) for in-stent restenosis (ISR) treatment. Background BVS has been proposed as alternative for ISR treatment. To date a direct comparison between BVS and DES or DEB for ISR treatment is lacking. Methods We retrospectively analyzed all ISR lesions treated with BVS, DEB, and EES from January 2012 to December 2014. A total of 548 lesions (498 patients) were included. By applying two propensity-score matching, 93 lesions treated with BVS were compared with 93 lesions treated with DEB, and 100 lesions treated with BVS were compared to 100 lesions tr…

Malemedicine.medical_specialtyTime Factorsmedicine.medical_treatmentUrology030204 cardiovascular system & hematologyProsthesis DesignBalloonRisk AssessmentCardiac CathetersCoronary Restenosis03 medical and health sciences0302 clinical medicineCoated Materials BiocompatibleRestenosisRisk FactorsAbsorbable ImplantsmedicineHumansRadiology Nuclear Medicine and imagingEverolimus030212 general & internal medicineAngioplasty Balloon CoronaryPropensity ScoreAgedRetrospective StudiesBioresorbable vascular scaffoldin stent restenosibusiness.industryIncidence (epidemiology)percutaneous coronary interventionStentPercutaneous coronary interventionCardiovascular AgentsDrug-Eluting StentsGeneral MedicineMiddle Agedmedicine.diseaseTreatment OutcomeItalyDrug-eluting stentPropensity score matchingFemalebioresorbable vascular scaffolddrug eluting balloonCardiology and Cardiovascular Medicinebusinessdrug eluting stent
researchProduct

Hybrid Coronary Percutaneous Treatment with Metallic Stents and Everolimus-Eluting Bioresorbable Vascular Scaffolds: 2-years Results from the GABI-R …

2019

The limitations of the first-generation everolimus-eluting coronary bioresorbable vascular scaffolds (BVS) have been demonstrated in several randomized controlled trials. Little data are available regarding the outcomes of patients receiving hybrid stenting with both BVS and drug-eluting stents (DES). Of 3144 patients prospectively enrolled in the GABI-Registry, 435 (age 62 &plusmn

medicine.medical_specialtyPercutaneousmedicine.medical_treatmentMedizinlcsh:Medicine030204 cardiovascular system & hematologyKoronare HerzkrankheitRevascularizationAbsorbable implantsCoronary artery diseaseArticleCoronary artery diseasedrug eluting stents03 medical and health sciences0302 clinical medicineDrug-eluting StentMedizinische Fakultätstent bioresorbableMedicine030212 general & internal medicineMyocardial infarctionddc:610Drug-eluting stentsTissue scaffoldsEverolimusbusiness.industrylcsh:RStentGeneral Medicinemedicine.diseaseThrombosisSurgeryConventional PCIbusinessDDC 610 / Medicine & healthcoronary artery diseasemedicine.drugJournal of Clinical Medicine
researchProduct